Integra LifeSciences (NASDAQ: IART) reported Q1 EPS of $0.48, $0.16 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $354.3 million versus the consensus estimate of $363.24 million.

2020 Full-Year Outlook

Given the existing uncertainty related to COVID-19, the Company’s guidance for the full-year 2020, issued on February 19, 2020, remains withdrawn as announced on April 7, 2020.

Supplemental financial and operational information is included in a presentation that can be found in the "Investor" section of the Company's website at investor.integralife.com under "Events & Presentations".

In the future, the company may record, or expects to record, gains or losses, expenses, or charges as described in the Discussion of Adjusted Financial Measures below, which will be excluded from the calculation of adjusted EBITDA, adjusted earnings per share for historical periods and in adjusted earnings per share guidance.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.